International Journal of Public Health Science (IJPHS) Vol. 10, No. 4, December 2021, pp. 758~763 ISSN: 2252-8806, DOI: 10.11591/ijphs.v10i4.20919  758 Journal homepage: http://ijphs.iaescore.com Evaluation of sensitivity and spesitivity as COVID–19 screening method Atikah Nurhesti 1 , Solikhah Solikhah 2 , Sitti Nur Djannah 3 1 Sleman Health Office, Sleman Regency Office, Indonesia 1,2,3 Department of Public Health, Faculty of Public Health, Universitas Ahmad Dahlan, Yogyakarta, Indonesia Article Info ABSTRACT Article history: Received Mar 1, 2021 Revised Aug 16, 2021 Accepted Aug 25, 2021 Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Antibody rapid test is one of the COVID-19 screening tests that can be used in the community. The accuracy of the rapid antibody methods needs to be appropriately assessed, it is necessary to carry out a diagnostic accuracy study using a pairwise sensitivity and specificity analysis. This research aimed to assess the sensitivity and specificity of COVID-19 rapid tests, also assesses positive predictive value (PPV) and negative predictive value (NPV) of the rapid antibody test as a method of screening for COVID-19 in Sleman Regency, Indonesia. In total, 118 respondents who have contact with COVID-19 patients and have symptoms were enrolled in this study. The study was conducted on 118 patients who had been in contact with confirmed COVID- 19 118 patients who met the close contact criteria were conducted a rapid antibody test. 64.41% patients were reactive. Real-time polymerase chain reaction (RT PCR) as a gold standard was also carried out for all patients and 63.56% affirmed positive for COVID-19. The sensitivity value was 97.33%, and the specificity value was 93.02%, while the positive predictive value (NPP) was 96.05%, and the negative predictive value (NPN) was 95.24%. These results meet the minimum recommendations for the screening method. Keywords: Antibody rapid tes COVID-19 Screening Sensitivity Specificity This is an open access article under the CC BY-SA license. Corresponding Author: Atikah Nurhesti Sleman Health Office Sleman Regency Office, Indonesia Email: atikahnurhesti@gmail.com 1. INTRODUCTION Coronavirus disease (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 transmission occurs from symptomatic patients through droplets that come out when coughing or sneezing. Meanwhile, cases related to transmission from asymptomatic patients generally have a history of close contact with COVID-19 patients [1]. The first cases of COVID-19 were reported in Indonesia on March 2, 2020, totaling two cases. Data shows that there are 1,528 confirmed cases and 136 deaths in March 2020 [2]. Meanwhile, the COVID-19 case in Sleman Regency, Indonesia was first recorded on March 18, 2020. Based on data from the Sleman Regency Health Service, on July 31, 2020, there were 233 cases, with eight of them dying, so the mortality rate reached 3.43% [3]. The fact that the entire world has been exposed to COVID-19 is causing the economy to disrupt. Therefore to re-open economic activity, health care encourages antibody tests for screening COVID-19 in the community [4]. The rapid test is use as a choice because it can detect immunoglobulin M (IgM) as a form of the body's defense response against viral infections. It also detects Immunoglobulin G (IgG), which is an immunological and immune memory. The process of forming IgG and IgM antibodies as a result of infection